Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Xu, Feng ^a,b   Li, Xiao ^a,b   Chang, Chun Kang ^a,b   Guo, Juan ^a   Wu, Ling Yun ^a   He, Qi ^a   Zhang, Zheng ^a   Zhu, Yang ^a   Gu, Shu Chen ^a   Shi, Wen Hui ^a   Song, Lu Xi ^a   Su, Ji Ying ^a   Zhou, Li Yu ^a   Zhang, Xi ^a   Wu, Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; LENALIDOMIDE; CD34 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD34+ B LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VALIDITY; ADOLESCENT; BLOOD TRANSFUSION; COHORT ANALYSIS; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROCEDURES; STEM CELL; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BLOOD TRANSFUSION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897759689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088706     Document Type: Article

References (29)

1. Li X, Bryant CE, Deeg HJ (2004) Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 80: 140-145. (Pubitemid 39201567)
2. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, et al. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102: 394-403. (Pubitemid 36759682)
3. Dellaporta MG, Malcovati L, Travaglino E, Invernizzi R, Lazzarino M, et al. (2006) Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. leukemia 20: 549-555.
4. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, et al. (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108: 1037-1044. (Pubitemid 44154642)
5. Lorand-Metze I, Ribeiro E, Lima CS, Batista LS, Metze K (2007) Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 31: 147-155. (Pubitemid 44854190)
6. Stachurski D, Smith BR, Pozdnyakova O, Anderson M, Xiao ZF, et al. (2008) Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 32: 215-224. (Pubitemid 351215540)
7. Xu F, Li X, Wu L, He Q, Zhang Z, et al. (2010) Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol 149: 587-597.
8. Chu SC, Wang TF, Li CC, Kao RH, Li DK, et al. (2011) Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 35: 868-873.
9. Loken MR, Shah VO, Dattilio KL, Civin CI (1987) Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70: 1316-1324. (Pubitemid 18026132)
10. Xiao M, Dooley DC (2000) Cellular and molecular aspects of human CD34+ CD38- precursors: analysis of a primitive hematopoietic population. Leuk Lymphoma 38: 489-497. (Pubitemid 30614533)
11. Tien HF, Wang CH (1998) CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 31: 93-98. (Pubitemid 28428752)
12. Font P, Subira D, Mtnez-Chamorro C, Castańón S, Arranz E, et al. (2006) Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res 30: 957-963. (Pubitemid 43831185)
13. Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, et al. (2009) Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica 94: 1160-1163.
14. Zhang H, Li SY (2010) Research progression of CD133 as a marker of cancer stem cells. Chin J Cancer 29: 243-247.
15. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, et al. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31: 727-736. (Pubitemid 46855901)
16. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
17. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465.
18. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, et al. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25: 3503-3510. (Pubitemid 47315575)
19. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, et al. (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98: 979-987.
20. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, et al. (2002) Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100: 3887-3896. (Pubitemid 35396853)
21. Arjan A, Theresia M, August H, Angelika M, Vincent HJ, et al. (2008) Identification of distinct prognostic sub- groups in low- and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 111: 1067-1077.
22. van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, et al. (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometric in myelodysplastic syndromes. Haematologica 94: 1124-1134.
23. Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, et al. (2012) Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 97: 1209-1217.
24. Sperling C, Schwartz S, Büchner T, Thiel E, Ludwig WD (1997) Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica 82: 617-621. (Pubitemid 28023263)
25. Zheng Z, Qianqiao Z, Qi H, Feng X, Chunkang C, et al. (2010) In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. Exp Hematol 38: 677-684.
26. Zheng Z, Feng X, Xiao L, Qianqiao Z, Qi H, et al. (2011) Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes. Eur J Haematol 86: 47-56.
27. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, et al. (2011) NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 9: 30-56.
28. Itzykson R, Fenaux P (2012) Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 19: 65-70.
29. Weinberg OK, Arber DA (2010) Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia 24: 1844-1851.